Join us Oct. 17 for a Fireside Chat with Jim Greenwood, senior policy advisor, DLA Piper, former U.S. Congressman & CEO of BIO plus Ron Philip, CEO, Spark Therapeutics & John Crowley, CEO, Amicus Therapeutics! <<Register here>>
Scott Willett, PhD Director of Academic Affairs, Professor of Experimental Therapeutics and Translational Medicine

Scott Willett, PhD

Dr. Willett has 30+ years of experience in the biopharmaceutical industry developing recombinant protein therapeutics. Prior to serving at VP of Biopharmaceutical Development at Promedior, Dr. Willett led process development at Neose Technologies. Before joining Neose, Dr. Willett was a Process Development Scientist at Amgen. Dr. Willett holds a Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco, and a Bachelor of Science degree in Chemical Engineering from the University of Michigan at Ann Arbor.

Specialties: recombinant therapeutic protein product development and manufacturing

← Back to Principal Investigators